Learn More About Ingrezza Uses and General Treatment Information

Ingrezza is the brand name for valbenazine, a prescription medicine classified as a vesicular monoamine transporter 2 inhibitor. It is approved for adults with tardive dyskinesia and for chorea associated with Huntington disease. Tardive dyskinesia can involve repetitive and involuntary movements, while chorea associated with Huntington disease can cause irregular, uncontrolled movements. Ingrezza works by affecting the release and storage of certain chemical messengers involved in movement control.

Understanding the Purpose and Usage of Ingrezza

Ingrezza is used under medical supervision to help manage specific movement symptoms. The prescribing information states that the medicine can be taken orally with or without food. The usual starting dose is 40 mg once daily. For tardive dyskinesia, the recommended dosage is generally increased to 80 mg once daily after one week, although 40 mg or 60 mg may be considered depending on response and tolerability. For Huntington disease chorea, dosage increases are generally made in 20 mg increments every two weeks, with 80 mg once daily being the recommended dosage.

Important general considerations include:

• Ingrezza should be taken according to the dosage prescribed by a healthcare professional.
• Patients should not change the dose or stop treatment without medical guidance.
• People with moderate or severe liver impairment may require a dosage of 40 mg once daily.
• People identified as CYP2D6 poor metabolizers may also require a 40 mg once-daily dosage.
• Ingrezza can interact with certain medicines, including some CYP3A4 and CYP2D6 inhibitors and monoamine oxidase inhibitors.

Important Safety Information and General Considerations

Like other prescription medicines, Ingrezza can cause side effects and requires appropriate medical monitoring. Somnolence, meaning sleepiness or drowsiness, is among the commonly reported adverse reactions in people treated for tardive dyskinesia. In people treated for Huntington disease chorea, reported adverse reactions include somnolence, lethargy or sedation, rash, urticaria, and insomnia. The medication may also cause QT interval prolongation and has warnings concerning hypersensitivity, neuroleptic malignant syndrome, and Parkinsonism.

Key considerations include:

• People with Huntington disease should be monitored for depression, suicidal thoughts, or unusual behavioral changes.
• Ingrezza may cause sleepiness or sedation and can affect activities such as driving or operating machinery.
• Patients should inform their healthcare professional about other medicines they take.
• A healthcare professional should be informed about liver problems, heart rhythm conditions, pregnancy, or breastfeeding before treatment.
• Signs of a serious allergic reaction require prompt medical attention.

Ingrezza is a specialized medication intended for particular movement disorders, and its suitability varies from person to person. The information above provides general educational information rather than individualized medical advice. Patients should follow the prescribing instructions provided by their healthcare professional and consult them with questions about dosage, side effects, interactions, or changes in treatment.